CoChat

The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Purpose Candida glabrata is an increasing cause of candidemia, especially at cancer and bone marrow transplant centers where fluconazole is used for antifungal prophylaxis. This yeast is less susceptible to fluconazole in vitro than is Candida albicans. We compared the characteristics of patients who had C. glabrata and C. albicans candidemia at a large cancer center.Subjects and methods We searched the microbiological laboratory reports and identified 116 cases of C. glabrata candidemia between 1993 and 1999. The 116 cases of C. albicans candidemia that occurred most closely in time (before or after each case of C. glabrata candidemia) served as the control group. Data were collected from patients' medical records.Results When compared with patients who had C. albicans infection, patients with C. glabrata candidemia more often had an underlying hematologic malignancy (68 [59%] vs. 26 [22%], P = 0.0001), had an Acute Physiology and Chronic Health Evaluation (APACHE) II score > or =16 (55 [48%] vs. 28 [25%], P = 0.0002), and received fluconazole prophylaxis (57 [49%] vs. 8 [7%], P = 0.0001). Patients with C. albicans candidemia more often had concomitant infections (101 [87%] vs. 78 [67%], P = 0.0003) and septic thrombophlebitis (11 [10%] vs. 2 [2%], P = 0.01). Among patients treated with antifungal therapy, those with C. albicans candidemia had a significantly greater overall response to therapy (83/104 [80%] vs. 60/97 [62%], P = 0.005) and to primary therapy (74/104 [71%] vs. 45/97 [46%], P = 0.0003). Amphotericin B preparations were not more effective than fluconazole (19/45 [42%] vs. 20/38 [53%], P = 0.5) in patients with C. glabrata candidemia. Fluconazole was less effective against C. glabrata than against C. albicans (20/38 [53%] vs. 57/74 [77%], P = 0.008).Conclusion C. glabrata has emerged as an important cause of candidemia, especially among neutropenic patients who receive fluconazole prophylaxis.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0002-9343(01)01130-5

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 24 · Cited by 209

Metadata

Authors
Bodey, G. P., Mardani, M., Hanna, H. A., Boktour, M., Abbas, J., Girgawy, E., Hachem, R. Y., Kontoyiannis, D. P., & Raad, I. I.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Raad, Issam I
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
2002-04
Volume
112
Issue
5
Pages
380-385
ISSN
0002-9343 (ISSN-L)
OpenAlex
W1987925654
Cited by
209
References
24
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 5 · 2015: 8 · 2014: 8 · 2013: 3 · 2012: 10
FWCI
9.71
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The American Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
Keywords
Candida glabrata, Candida albicans, candidemia, fungemia, immunocompromised patients, cancer patients, hematologic malignancies, fluconazole prophylaxis, antifungal therapy, amphotericin B, fluconazole resistance, septic thrombophlebitis, concomitant infection, APACHE II score, risk factors, treatment response
MeSH terms
Amphotericin B, Antifungal Agents, Candida albicans, Candidiasis, Female, Humans, Male, Middle Aged, Neoplasms, Neutropenia, Postoperative Complications, Regression Analysis, Fluconazole, Case-Control Studies, Bone Marrow Transplantation, Fungemia, Treatment Outcome, APACHE

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. https://app.cochat.ai/papers/10.1016/s0002-9343(01)01130-5
The paper
Bodey, G. P., Mardani, M., Hanna, H. A., Boktour, M., Abbas, J., Girgawy, E., Hachem, R. Y., Kontoyiannis, D. P., & Raad, I. I. (2002). The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. The American Journal of Medicine. https://doi.org/10.1016/s0002-9343(01)01130-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.